Form 4/A for KPRX KIORA PHARMACEUTICALS INC
Accepted 2021-11-22 00:00:00 ET · period of report 2021-10-21 · accession 0001104659-21-142530 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2021-11-22 | 2021-10-21 | KPRX | Daniels Eric Joseph | Chief Development Off | A - Grant | — | +9,520 | 9,520 | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-10-21 | A | A | 9,520 | — | 9,520 | D | — | — | (F1) These shares were omitted from the Reporting Person's Form 4 filed on November 10, 2021. (F2) Received by the Reporting Person in connection with the acquisition by the issuer of all of the outstanding securities of Bayon Therapeutics, Inc. on October 21, 2021. |